Multimodal Therapy With Metformin, Inositol and Dietary Restriction Improves Insulin Resistance and Endocrine Outcomes in Women With Polyendocrine Metabolic Ovarian Syndrome: A Randomized Controlled Trial
Authors' conclusion
Multimodal therapy was associated with superior metabolic and reproductive outcomes compared with single-modality interventions in women with PMOS.
Study context
- Population
- Women aged 18–35 years with polyendocrine metabolic ovarian syndrome (PMOS) (formerly polycystic ovary syndrome (PCOS)) by Rotterdam criteria
- Participants
- 192 women
- Comparison
- Combination therapy vs metformin vs inositol vs calorie-restricted diet
- Primary endpoint
- Changes in BMI and insulin resistance (HOMA-IR)
- Follow-up
- 12 weeks
Methodological details12-week, Findings reflect early improvements rather than sustained normalisation, given short follow-up
- 12-week
- Findings reflect early improvements rather than sustained normalisation, given short follow-up
Primary result
As reported in the abstract
Combination therapy: greatest reduction in HOMA-IR (95% CI - 2.82 to −2.46, p < 0.001)
- 2.64
Combination therapy: greatest reduction in body mass index (BMI) (95% CI - 3.05 to −2.55, p < 0.001)
- 2.8 kg/m²
Secondary outcomes
Menstrual cycle regularisation · 12 weeks · across all groups, Chi-square test
P < 0.001
Original publication
Multimodal Therapy With Metformin, Inositol and Dietary Restriction Improves Insulin Resistance and Endocrine Outcomes in Women With Polyendocrine Metabolic Ovarian Syndrome: A Randomized Controlled Trial. Clin Endocrinol (Oxf). Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →